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Diﬃcult to detect, ovarian cancer typically presents at an advanced stage. Signiﬁcant progress has been achieved in the treatment
of ovarian cancer with therapeutics focused on DNA replication or cell division. However, despite sensitivity to induction
chemotherapy the majority of patients will develop recurrent disease. Conventional agents for recurrent disease oﬀer little in
terms of long-term responses. Various targeted therapeutics have been explored in the management of ovarian cancer. These
include monoclonal antibodies to epidermal growth factor receptors, small molecule tyrosine kinase inhibitors, monoclonal
antibodiesdirectedatthevascularendothelialgrowthfactor(bevacizumab),andthesmalltyrosinekinaseinhibitorsthattargetthe
vascular endothelial growth factor receptor. Recently, several other agents have come forth as potential therapeutic agents in the
management of ovarian cancer. These include monoclonal antibodies to the folate receptor, triple angiokinase inhibitors, PARP
inhibitors, aurora kinase inhibitors, inhibitors of the Hedgehog pathway, folate receptor antagonists, and MTOR inhibitors.
1.Introduction
Various targeted therapeutics have been explored in the
management of ovarian cancer. These include monoclonal
antibodies to Her 2 neu [1, 2] and other epidermal growth
factor receptors [3] (i.e., Trastuzumab [1], Pertuzumab
[2], and EMD 7200 [3]), small molecule tyrosine kinase
inhibitors thattargeted the various EGFR receptors (geﬁtinib
[4], erlotinib [5], CI-1033 [6]), monoclonal antibodies
directed at the vascular endothelial growth factor [7–19]
(bevacizumab), and the small tyrosine kinase inhibitors
that target the vascular endothelial growth factor receptor
[20–25]. Recently, several other agents have come forth as
potential therapeutic agents in the management of ovarian
cancer. These include monoclonal antibodies to the folate
receptor, triple angiokinase inhibitors, PARP inhibitors,
aurora kinase inhibitors, inhibitors of the Hedgehog path-
way, folate receptor antagonists, and MTOR inhibitors.
This paper will explore the current data on the various
targeted approaches in ovarian cancer. Attention will be
directed at understanding the molecular mechanisms of
these agents balanced with their application to clinical
practice.
2. Angiogenesis
Enthusiasm for cytotoxic agents in the management of
ovarian cancer has been tempered by the emergence of
resistance. As such, a focus on alternative innovative thera-
peutics has emerged. One such direction is the inhibition of
angiogenesis. Angiogenesis is one of the cardinal processes
leading to invasion and metastasis of solid tumors. The
angiogenic-signaling pathwaymay be triggered by the release
of angiogenic ligands such as the vascular endothelial
growth factor from tumor cells. Tumor angiogenesis is well
established as essential for the growth and metastasis of solid
tumors, [26–28] This process involves the recruitment of
mature vasculature and circulating endothelial cells [29, 30]
and proangiogenic soluble mediators one of which includes
the vascular endothelial growth factor (VEGF) [31]. This
factor has several known activities [31], such as mitogenesis,
angiogenesis, endothelial survival, enhancement of vascular
permeability, and eﬀects on hemodynamic status. In ovarian
cancer increased levels of VEGF are associated with poor
prognosis and have been conﬁrmed in multivariate analysis
as an independent prognostic indicator of survival [28, 32–
38]. Given the poor long-term responses appreciated with2 Journal of Oncology
conventional cytotoxic agents that target VEGF have taken
center stage.
Agents targeting angiogenesis include monoclonal anti-
bodies to the VEGF ligand [7–19], small tyrosine kinase
inhibitors that target the vascular endothelial growth factor
receptor[20–25],andsolubledecoyVEGFreceptors[39,40].
The most studied agent to date has been bevacizumab, a
recombinant humanized monoclonal antibody to the VEGF
ligand.
To date several investigators [7–19]( Table 1)h a v e
explored bevacizumab as a single agent or in combination
with chemotherapy in the management of advanced ovarian
cancer.
Several studies in both the upfront and in the recurrent
setting are underway. GOG 218 is a randomized placebo
controlled three-arm study examining the role of beva-
cizumab in combination with carboplatin and paclitaxel
and also as a maintenance therapy. ICON-7 is a two arm
trial comparing carboplatin and paclitaxel (six cycles) versus
carboplatin, paclitaxel, and bevacizumab (7.5mg/kg) for six
cycles followed by 12 cycles of maintenance bevacizumab.
Campos et al. [20] is conducting a phase II trial of carbo-
platin/paclitaxel/bevacizumabinoptimallyandsuboptimally
debulked patients. Patients achieving a clinical complete
response, partial response, or stable disease are subsequently
randomized to either bevacizumab for 12 months or the
combination of bevacizumab and erlotinib. Preliminary
safety results have noted an increase in hypertension but to
date no evidence of gastrointestinal perforations.
Given the recent data that has emerged on the role
on intraperitoneal chemotherapy [41–43]i n v e s t i g a t o r sa r e
exploring the role of IP chemotherapy with IV bevacizumab.
Several abstracts were highlighted at the recent American
Society of Clinical Oncology meeting. Konner et al. [44]
and McKeekin et al. [45] in independent studies reported
the feasibility of utilizing bevacizumab (IV) in conjunction
withintraperitonealtherapy.Onebowelperforation[44]was
notedtheKonnerstudywhileMcKeekinetal.[45]colleagues
noted one deep venous thrombosis and one ﬁstula.
In the recurrent setting several trials are being con-
ducted. The OCEANS trial is a randomized study of
carboplatin/gemcitabine and bevacizumab (NCT 00434642)
versus carboplatin/gemcitabine. GOG 213 (Figure 1)i sr a n -
domized trial in recurrent ovarian cancer patients. Patients
are stratiﬁed as to whether or not they are surgical candi-
dates. If the patients are deemed to be surgical candidates
they are randomized to surgery or no surgery followed
by randomization to chemotherapy. If patients are ran-
domized to no surgery they are subsequently randomized
to carboplatin and paclitaxel or carboplatin/paclitaxel and
bevacizumab.
The combination of carboplatin/DOXIL and beva-
cizumab is also being studied. The later trial may prove
to be intriguing given the recently reported results of the
CALYPSO trial [46]. In the CALYPSO trial the combina-
tion of Carboplatin-Doxil demonstrated a superior ther-
apeutic index (beneﬁt/risk ratio) versus current standard,
carboplatin-paclitaxel.
Surgical candidate or not
Yes No
Randomize Randomize
Surgery No surgery
Chemo randomization
Carboplatin +
paclitaxel
Carboplatin +
paclitaxel +
bevacizumab
Figure 1: GOG 213.
3.SmallMoleculesthatTarget
theVEGFRReceptor
Small molecule tyrosine kinase inhibitors that target the
vascular endothelial growth factor receptor are currently
being investigated in numerous clinical trials. AZD2171
(Cediranib) is a novel oral tyrosine kinase inhibitor of
VEGFR2, VEGFR1, and c-kit. Matulonis et al. [21]r e p o r t e d
the initial results of this agent in the management of patients
with recurrent ovarian cancer. Five patients had conﬁrmed
partial responses with an overall response rate of 18.5%.
Three patients had stable disease lasting 30, 27+, and 24
weeks. Hirte et al. [22] reported a response rate of 40.5%
in platinum sensitive patients and a response rate of 29%
in platinum resistance disease with AZD 2171 (Cediranib).
Prevalent side eﬀects included fatigue and hypertension.
Currently, ICON-6 is conducting a study of AZD2171
(Cediranib) in platinum sensitive relapsed ovarian cancer in
a three arm randomized placebo-controlled phase III trial in
combination with paclitaxel and carboplatin. (Figure 2).
Pazopanib is tyrosine kinase inhibitor of vascular
endothelial growth factor receptor (VEGFR) −1, −2, and
−3, platelet-derived growth factor receptor (PDGFR) −α
and −β, and c-Kit. Friedlander et al. [24]h a v er e p o r t e d
activity with pazopanib in women with advanced epithelial
ovarian cancer. Eleven of 36 subjects (31%) experienced a
cancer antigen-125 (CA-125) response to pazopanib. Overall
response rate based on modiﬁed Gynecologic Cancer Inter-
group (GCIG) criteria (incorporating CA-125, Response
Evaluation Criteria in Solid Tumors (RECIST), and clinical
assessment) was 18% in subjects with measurable disease at
baseline and was 21% in subjects without measurable disease
at baseline. Median PFS was 84 days.
Sunitinib, an inhibitor that targets the VEGFR 1, 2,
3, and platelet–derived growth factor receptors, has also
been studied in the management of patients with recurrent
ovarian cancer. Biagi et al. [25] investigated the role of
sunitinib in the management of patients with recurrent
ovarian cancer. Sunitinib was administered at 50mg everyJournal of Oncology 3
Table 1: Current trials in ovarian/fallopian/peritoneal cancer.
Author N Prior lines Platinum S/R
∗/ﬁrst line Regimen∗∗ RR:CR + PR TTP/PFS median
B u r g e rRe ta l .[ 7]6 2 1 - 2 + /+ Single 21 % PFS 4.7mo
Cannistra et al. [8]4 4 2 - 3 + /+ Single 15.9% PFS 4.4 mo
Garcia et al. [9]7 0 1 – 3+ /+ Combo 24% TTP 7.2 mo
Wright et al. [10]2 3 2 – 1 5 −/+ Combo 35 % TTP 5.6 mo
Chura et al. [11]1 5 5 – 1 5+ /+ Combo 43 % PFS 3.9 mo
Nimeiri et al. [12]1 3 1 – 3 + /+ Combo 15 % PFS 4.1 mo
Monk et al. [13]3 2 2 – 1 0−/+ Single 16 % PFS 5.5 mo
Simpkins et al. [14]2 5 2 – 1 2 −/+ Combo 28 % TTP 9.0 mo
McGonigle et al. [15]1 8 0 – 2 −/+ Combo 22% PFS 3.8 mo
Azad et al. [17] 13 NR NR Combo 46% NR
Micha et al. [16] 20 0 First line Combo 80% NR
Campos/Penson et al. [18, 19] 58 0 First line Combo 75% PFS:11mo
∗Enrolled patients: platinum sensitive/resistant/ﬁrst line.
∗∗Single bevacizumab or combination therapy with cytotoxic or other biological agents.
NR: not reported.
ICON 6
Randomized
Carboplatin/paclitaxel + placebo followed
by placebo for 18 months
Carboplatin/paclitaxel + Cediranib followed
by placebo for 18 months
Carboplatin/paclitaxel + Cediranib followed
by Cediranib for 18 months
Figure 2: ICON-6.
day on a 4-week on 2-week oﬀ schedule. Noted in this study
was the development of pleural eﬀusions during the 2-week
rest period. Of the seventeen patients that were studied 12%
of patients had a partial response, and 59% of patients had
disease stabilization. Currently the Harvard Cancer Center
Gynecological Group (NCT00768144) is conducting a phase
II trial using sunitinib in refractory ovarian caner patients.
The dose of sunitinib is held constant at 37.5mg every day.
AMG 706 is an investigational inhibitor of vascular
endothelial growth factor receptors 1, 2, and 3, platelet-
derived growth factor receptor, and stem-cell factor receptor.
A Phase II Evaluation of AMG706 (NCT00574951) in the
Treatment of Persistent or Recurrent Epithelial Ovarian
Fallopian Tube or Primary Peritoneal Cancer is currently
active.
Matei et al. [26] reported on the activity of sorafenib in
patient with recurrent ovarian cancer. Sorafenib is a tyrosine
kinase inhibitor targeting raf and other receptor kinases
(VEGF-R, PDGF-R, Flt3, c-KIT). Patients received sorafenib
at 400mg QD. Patients in this study have a 3% partial
response, and 20% of patients had stable disease for > than
6 months. Toxicities included rash, metabolic abnormalities,
gastrointestinal, cardiovascular, and pulmonary toxicity.
4.VEGFTrap(Aﬂibercept)
VEGF trap (Aﬂibercept) is fusion protein containing the
VEGF binding regions of both VEGFR-1 and 2 linked
through the Fc region of a human IgG1. Aﬂibercept binds
VEGF-A and neutralizes all VEGF-A isoforms plus placental
growth factor. This agent is currently being explored in plat-
inum resistant ovarian cancer. Columbo et al. [39]r e p o r t e d
the results of VEGF Trap in patients with symptomatic
malignant ascites. Aﬂibercept, 4mg/kg, i.v. was administered
every 2 weeks, in patients with advanced ovarian cancer
andsymptomaticascitesrequiringfrequentparacentesis.Pri-
maryendpointwasrepeatparacentesisresponserate(RPRR)
deﬁned as at least a doubling of time to the ﬁrst paracentesis
compared to a baseline average. Patients received 1–13 cycles
of aﬂibercept. The authors reported that the time to the
ﬁrst paracentesis was 12–205 days. Eight out of ten evaluable
patients achieved a RPRR response as per protocol. Adverse
events included bowel obstruction, nausea, vomiting,
anorexia, edema, and 1 case of bowel perforation. Tew et al.
[40] reported the preliminary results of a randomized phase
II study in patients with recurrent platinum-resistant epithe-
lial ovarian cancer. VEGF Trap was (2 or 4mg/kg) adminis-
tered intravenously every 2 weeks in patients with recurrent4 Journal of Oncology
ovarian cancer was conducted. Five partial responses in a
sample size of 45 patients (11%) were reported.
5. EpidermalGrowth Factor Inhibitors
In addition to the VEGF inhibitors, the epidermal growth
factor receptor (EGFR) has emerged as an attractive target
[47–49]. The activation of EGFR signaling pathways is
known to increase proliferation, angiogenesis, and decrease
apoptosis. Several strategies that target the EGFR in gyne-
cologic cancers have included monoclonal antibodies [1–3],
(trastuzumab, pertuzumab, EMD7200) and tyrosine kinases
inhibitors [4–6] (geﬁtinib, erlotinib, lapatinib and CI-1033).
Bookman and colleagues [1, 50] reported a response rate of
7% in a phase II trial of ovarian cancer patients treated with
trastuzumab. Kaye et al. [51], Amler et al. [52], and Makhija
et al. [53] in independent studies examined pertuzumab, a
humanized recombinant monoclonal antibody that inhibits
the dimerization of HER2 with EGFR, HER 3, and HER4,
in patients with ovarian cancer. As a single agent there
were only modest responses. Gordan et al. [54] recently
published the clinical activity of pertuzumab in advanced
ovarian cancer. There were ﬁve partial responses (response
rate 4.3%), eight patients (6.8%) with stable disease lasting
at least 6 months, and 10 patients with CA-125 reduction
of at least 50%. Median progression-free survival (PFS) was
6.6 weeks. Twenty eight percent of the tumor biopsies were
pHER2+ by ELISA. Of note the progression free survival for
pHER2+ patients was 20.9 weeks (n = 8) versus 5.8 weeks for
pHER2−.
Several studies are ongoing. The EORTC have recently
completed a trial investigating erlotinib as maintenance
therapy following ﬁrst-line chemotherapy in patients with
ovarian cancer (NCT00263822). A phase II open label
trial of erlotinib and bevacizumab is being conducted by
Alberts et al. in patients with advanced ovarian cancer
(NCT00696670).
Unlike other disciplines there is lack of data in the
gynecological literature on who, if any, will beneﬁt from
EGFRinhibitors.Schilderetal.[55]reportedthatinasample
size of 55 ovarian cancer patients 3.6% had mutations in
the EGFR tyrosine kinase domain and that the mutation
correlated with a response to geﬁtinib. Exploratory analyses
in the pertuzumab studies [51–53] suggested that patients
with platinum resistant disease and low levels of HER3
mRNA might beneﬁt from pertuzumab. An additional study
by Tanner et al. [56] demonstrated an inﬂuence of HER 3
expression on the survival of patients with ovarian cancer.
Selection of ovarian cancer patients with EGFR ampli-
ﬁcations, increased pHER2, and low expression of HER 3
ratios may represent the selected few that may respond to
EGFR inhibitors.
6. Combination Therapy with EGFR and
VEGFInhibitors
EGFR activation has been reported to promote VEGF [57]
secretion. Several clinical studies are exploring the combi-
nation of EGFR inhibitors and VEGF inhibitors. Nimeiri
et al. [12] investigated the clinical activity and safety of
bevacizumab and erlotinib patients with recurrent ovarian,
primary peritoneal, and fallopian tube cancer. In this study
patients were heavily pretreated. Two patients had a fatal
bowel perforation.
Currently investigators at the Harvard Cancer Center
are conducting a randomized phase II trial of Beva-
cizumab or Bevacizumab and Erlotinib as First Line
Consolidation Chemotherapy after Carboplatin, Paclitaxel,
and Bevacizumab (CTA) Induction Therapy for Newly
Diagnosed Advanced Ovarian, Fallopian Tube and Primary
Peritoneal Cancer & Papillary Serous Mullerian Tumors
(NCT00520013) [20].
7.PlateletDerivedGrowthFactorInhibitors
Platelet-derived growth factor (PDGF) a prototype for
understanding the function of growth factors and receptor
tyrosine kinases (TK) [58] induces cell growth and sur-
vival, transformation, migration, vascular permeability, and
wound healing [59]. PDGF receptor (PDGFR) activation
in cancer occurs as a consequence of gene ampliﬁcation,
chromosomal rearrangements, or activating mutations [60–
62]. PDGFR activation is critical to tumor initiation in
addition to functioning as a mediator of connective tissue
stroma [63].
PDGFR has been shown in 50–80% of ovarian tumors
[63].SeveralagentsthattargetthePDGFRhavebeenstudied.
These include imatinib mesylate [63–66], sorafenib, [17, 26],
sunitinib [25], dasatinib [67], 3G3 [68], and CDP 860 [69].
Imatinib mesylate is a selective Abl, c-Kit, and PDGFR
inhibitor. Three phase II clinical trials [64, 70, 71] in patients
with ovarian cancer failed to demonstrate clinical beneﬁt.
The GOG (170M) is currently studying dasatinib in
a Phase II Evaluation of Dasatinib in the Treatment of
Persistent or Recurrent Epithelial Ovarian, Fallopian Tube,
or Primary Peritoneal Carcinoma
BIBF1120 [72] is a novel agent. It is a triple angiok-
inase inhibitor that targets the VEGFR, PDGRF, and the
ﬁbroblast growth factor receptor (FGFR). Sustained pathway
inhibition is a distinct feature of this agent. Ledermann et
al. [73] recently conducted a randomized phase II placebo-
controlled trial using maintenance therapy to evaluate the
vascular targeting agent BIBF 1120 following treatment of
relapsed ovarian cancer. The 36-week PFS rate for BIBF 1120
was 15.6% and 2.9% for placebo. The authors concluded
that maintenance BIBF 1120 could delay disease progression
in ovarian cancer patients who had previously responded to
chemotherapy.
8.Folate Receptor Inhibitors
Folic acid is an essential vitamin and of importance for
one-carbon transfer processes medicated by enzyme systems
involved in DNA synthesis [74]. Increased expression of
α-FR has been described in various tumor tissues, including
ovarian, endometrial, and breast cancer [75]. While theJournal of Oncology 5
Table 2: PDGF-targeted therapies in ovarian cancer.
clinical trial.gov ID Therapeutic regimen Study PI
NCT00913835 Doxil ± IMC 3G3 in platinum refractory or resistant EOC W. McGuire
NCT00768144 Sunitinib in refractory/recurrent ovarian, fallopian tube, or peritoneal cancer S. Campos
NCT00437372 Sunitinib and radiation therapy A.D i c k e r
NCT00792545 Dasatinib + bevacizumab in surgically metastatic, or unresectable solid tumors E. Kohn
NCT00672295 Dasatinib + paclitaxel + carboplatin in ovarian, fallopian tube, and peritoneal
cancer
A. Secord
NCT00436215 Sorafenib + bevacizumab in recurrent/refractory ovarian, fallopian tube, or
peritoneal cancer
E. Kohn
NCT00526799 Sorafenib + topotecan in platinum resistant EOC D. Matei
NCT00390611 Paclitaxel + carboplatin ± sorafenib for ﬁrst-line therapy for EOC J. Hainsworth
NCT00096200, Sorafenib + paclitaxel + carboplatin in recurrent platinum-sensitive ovarian,
fallopian tube, or peritoneal cancer
V. von Gruenigan
NCT00510653 Gleevac study for patients with ovarian cancer D. Gershenson
NCT00840450 Gleevac and paclitaxel with recurrent mullerian cancers F. Muggia
function of α-FR in cancers is not fully understood,
folates are critical metabolites for nucleotide synthesis and
methylation reactions. Its overexpression might confer a
tumor growth advantage by increasing folate availability to
cancer cells [75]. Over 90% of nonmucinous ovarian cancers
overexpress α-FR [76].
Several strategies have been employed to target the
folate receptor. Some of these include the use of anti-α-FR
antibodiesorfolicacidconjugates.Therehasalsobeenrecent
researchtoshowthatα-FRmayhaveapotentialasatargetfor
immunotherapeutic approaches in ovarian cancer. α-FR is
a tumor-associated antigen that induces detectable immune
responses in 70% of patients with breast and ovarian cancer
[77]. The presence of endogenous immune reactivity raises
the possibility that the immune response could be further
enhanced by vaccines targeting the α-FR. Hernando et al.
[78] presented a case of a women with recurrent epithelial
ovarian cancer treated with a vaccination regimen created
with autologous dendritic cells engineered with mRNA-
encoded α-FR [78]. An initial contrast-enhanced CT of
the abdomen before vaccination had shown para-aortic
lymph node metastasis at the level of the left renal hilus
and lower abdominal aorta. Follow-up CT 16 months after
last vaccination depicted a more than 50% regression of
lymph node metastasis and a dramatic decrease in CA125
concentrations 4 weeks after the ﬁrst vaccination [78].
Farletuzumab (MORAb-003) is a monoclonal antibody
to α-FR that activates antibody-dependent cell-mediated
cytotoxicity and complement-mediated toxicity [79]. In a
recent Phase II trial of 54 patients [80]w i t hp l a t i n u m -
sensitive relapsed disease patients who received combination
therapy exhibited a prolongation of their remission when
compared to their previous remission. Ongoing clinical
trials looking at Farletuzumab include a Phase III trial
comparing the eﬃcacy and safety of intravenous carboplatin
and taxanes with and without farletuzumab in subjects with
ﬁrst platinum-sensitive relapse, a Phase II trial examining
intravenous paclitaxel with and without farletuzumab in
patients with ﬁrst platinum-resistant or refractory relapse.
EC145 is a drug that is speciﬁcally designed to enter
cancer cells via the folate vitamin receptor (FR). Early
clinical evidence in a small number of phase I patients
suggests that EC145 may have antitumor eﬀect in women
with advanced ovarian cancer. Current independent studies
include a study of EC145 in patients with advanced ovarian
and endometrial cancers (NCT00507741) and a study in
patients with platinum resistant ovarian cancer with a
combination of Doxil and EC145 Combination Therapy
(NCT00722592).
9. Poly-ADP-Ribose Polymerase (PARP)
Inhibitors
Between 5 and 10% of all ovarian cancer cases are associated
with inheriting a mutation in the BRCA1 or BRCA2 gene
[81]. The lifetime risk of ovarian cancer for BRCA1 and
BRCA2 mutation carriers is estimated at 40–50% and 10–
20%, respectively. BRCA1 and BRCA2 are essential for the
repairofdoublestrandDNAbreaks(DSBs)andmaintenance
of genomic stability [82].
Poly (ADP-ribose) polymerase (PARP) is a key nuclear
enzyme involved in the repair of DNA single-strand breaks
(SSBs) using the base excision repair pathway [83]. PARP-1
andPARP-2aretheonlymembersofthePARPfamilyknown
to be activated by DNA damage, and PARP-1 has been best
characterized.PARPinhibitionresultsintheaccumulationof
DNA SSBs, which may lead to DSBs. Thus, the use of PARP
inhibitors in BRCA mutation carriers uses the concept of
synthetic lethality and hence can be described a therapeutic
exploitation.
In the ﬁrst human phase I clinical trial using Ola-
parib (AZD2281, KU-0059436; AstraZeneca) an oral small-
molecule PARP-1 inhibitor, toxicities included nausea, vom-
iting, anorexia, and fatigue. Eﬃcacy has been reported.
Olaparib has shown antitumor activity in BRCA-associated
ovarian cancer [84, 85]. Fifty patients were treated at various
doses, of which 41 were BRCA1 mutation carriers, eight were6 Journal of Oncology
Table 3: α-folate receptor inhibitors and ovarian cancer.
Clinical trial.gov ID Therapeutic regimen Study PI
NCT00722592 Doxil and EC145in platinum resistant EOC R. Messmann
NCT00738699 MORAb-003 in ﬁrst platinum resistant or refractory relapsed EOC D. Chakraborty
NCT00849667 MORAb-003 in platinum sensitive, ﬁrst relapse EOC D. Chakraborty
BRCA2 mutation carriers and one had a compelling family
historyforBRCAmutation.Ofthe46patientswithevaluable
disease, 41% reached either a complete or partial response.
Eleven percent had meaningful stabilization of disease for
4 months, giving a total clinical beneﬁt rate of 52%. The
median response duration was 30 weeks.
Recently reported were the results of a phase II trial of
the oral PARP inhibitor Olaparib (AZD 2281) in BRCA-
deﬁcient advanced ovarian cancer [86]. An international,
phaseIIstudyexaminedtwocohortsofpatientsthatreceived
oral olaparib in 28-day cycles, initially at the MTD, 400mg
bid (33pts), and subsequently at 100mg bid (24pts). The
conﬁrmed overall response rate was 33% at 400mg bid dose
and 12.5% at 100mg bid dose. Clinical beneﬁt rate (ORR
and/or conﬁrmed ≥50% decline in CA125) was 57.6% at
400mg bid and 16.7% at 100mg bd. Toxicity was mild.
Olaparib is currently being evaluated in randomized
PhaseIItrialsinplatinum-sensitiverecurrentovariancancer,
and in known BRCA or high grade recurrent ovarian
cancer. It is also being compared with pegylated liposomal
doxorubicin in patients with BRCA mutated ovarian cancer
with a 0-12 month platinum-free interval (NCT00628251).
Other PARP inhibitors are also being evaluated in
BRCA mutation carriers with cancer, including AG0146999
(Pﬁzer) ABT888 (Abbott), BSI-201 (Bipar), INO-1001
(Inotek/Genentech), and MK4827 (Merck).
The use of PARP inhibitors might be extended to
sporadic ovarian cancers with homologous recombination
defects. These sporadic tumors seem to phenocopy BRCA1/2
deﬁcient tumors even though they do not possess the
germline mutations in either gene. This phenomenon is
called “BRCAness.” This can occur due to loss of heterozy-
gosity, hypermethlyation, and haploinsuﬃciency (inactiva-
tion of one BRCA allele), thereby, genetically silencing the
BRCA gene without an actual germline mutation. A recent
study suggests that over 50% of high-grade serous ovarian
cancer had loss of BRCA function, either by genetic or
epigenetic events [87]. A randomized placebo-controlled
trial of olaparib as a maintenance therapy in patients with
serous (sporadic) ovarian cancer at high risk for recurrence
is now underway.
10.AuroraKinaseInhibitors
Aurorakinases are protein kinases thatare important mitotic
regulators [88, 89]. They are central to many cellular
functions notably mitosis, centromere separation, as well as
mitotic spindle formation. Three aurora kinases (A, B, C)
exist.Theactivityofaurorakinaseiscellcycledependentand
active during the G2M phase of the cell cycle. Several inves-
tigators [88, 90, 91] have described the oncogenic potential
of these proteins. Aurora-A also phosphorylates the tumor
suppressor protein p53, resulting cell cycle progression [92].
Aurora A is overexpressed in 83% of human epithelial
ovarian carcinomas [93]. In addition, ampliﬁcation of
human chromosome 20q13.2, which contains Aurora-A,
frequentlyoccursinovariancancer[94].AurorakinaseAhas
been signiﬁcantly associated with tumor grade, FIGO stage,
and survival [93, 95].
Lin et al. [96] studied the role of MK-0457, a small
molecule pan-aurora kinase inhibitor in ovarian cancer cell
models.Twochemosensitivehumanovariancancercelllines,
HeyA8 and SKOV3ip1, were used to study the eﬀects of
aurora kinase inhibition. Additionally two chemoresistant
cell lines (Hey A8-MDR and A2780-CP-20) were also
studied. Both cell lines showed that aurora kinase inhibition
alone signiﬁcantly reduced tumor burden. Combination
treatment with docetaxel resulted in signiﬁcantly improved
reduction in tumor growth beyond that aﬀorded by doc-
etaxel alone (P < or = .03). Scharer et al. [97] also reported
that aurora kinase inhibitors synergize with paclitaxel to
induce apoptosis in ovarian cancer cells.
Manfredl et al. [98] reported the antitumor activity of
MLN8054,anorallyactivesmallmoleculeinhibitorofaurora
kinase.Growthofhumantumorxenograftsinnudemicewas
dramatically inhibited after oral administration of MLN8054
in human tumor xenografts. MLN8054 induced mitotic
accumulation and apoptosis. Given these ﬁndings MLN8054
is currently being explored in the management of patients
with platinum-refractory or resistant epithelial, fallopian, or
primary peritoneal carcinoma (NCT00853307).
11.Hedgehog Pathway Inhibitors
Hedgehog signaling plays a role in many processes such as
cell diﬀerentiation, growth, and proliferation. This pathway
is active during embryonic development and remains active
in the adult where it is involved in the maintenance of stem
cell populations.
The Hedgehog family [99] has several proteins which
function as signaling molecules. These include Sonic
hedgehog (Shh), Indian hedgehog (Ihh), and Desert
hedgehog (Dhh). There are two receptors that are in-
volved in the Hedgehog pathway. PATCHED1 is a
hedgehog receptor. In the absence of a ligand PATCHED1
inhibits SMOOTHENED, a transmembrane G-coupled
protein. However, when the ligand binds PATCHED1,
SMOOTHENED suppression is relieved resulting in
transcription of the Hedgehog genes. PATCHED1 orJournal of Oncology 7
Table 4: PARP inhibitors and ovarian cancer.
clinical trial.gov ID Therapeutic regimen Study PI
NCT00753545 AZD2281 in platinum sensitive EOC J. Lederman
NCT00679783 AZD2281 in known BRCA or recurrent EOC K. Gelman
NCT00749502 MK4827 in BRCA mutant ovarian cancer
NCT00664781 AG014699 in BRCA mutant ovarian cancer R. Plummer
NCT00647062 AZD2281 and carboplatin in BRCA mutant EOC E. Kohn
SMOOTHENED receptor mutations or overexpression of
the Hedgehog ligand leads to uncontrolled cell proliferation.
Bhattacharya et al. [99] studied the role of Hedgehog
signaling in ovarian cancer. They utilized a hedgehog path-
way blocker and studied the proliferation of ovarian tumors.
They noted that PATCHED1 is downregulated in ovarian
cancer and that this low level expression of the PATCHED1
contributed to the proliferation of ovarian cancer cells. Chen
et al. [100] also examined the expression and the functional
role of the hedgehog signal molecules in ovarian cancer.
They reported that the hedgehog molecules (Shh, Dhh,
Ptch, Smo, and Gli 1 proteins) were increased in malignant
disease. Decreased cell proliferation in ovarian carcinoma
cell lines was observed with Hedgehog pathway inhibitor-
cyclopamine.
Recently reported was the eﬀect of IPI-926 (Inﬁnity
Pharmaceuticals, Inc., Cambridge, Mass) a novel inhibitor
of the Hedgehog signaling pathway in ovarian cancer grafts.
Data revealed that treatment with cyclopamine, the natural
product of IPI-926 in animals with primary ovarian cancer
grafts, resulted in tumor growth inhibition. This agent is
currently being explored as a Phase I study in patients with
solid tumors (NCT00761696).
Currently recruiting is a study of GDC-0449 (Genentech,
Inc), a Hedgehog pathway inhibitor, as maintenance therapy
in patients with ovarian cancer in a second or third complete
remission. GDC-0449 willbeevaluatedinapproximately100
patients with ovarian cancer in second or third complete
remission in a randomized, placebo-controlled, double-
blind, multicenter Phase II trial. Patients are randomized
in a 1 : 1 ratio to receive either GDC-0449 or a placebo
comparator and are stratiﬁed based on whether their cancer
is in a second or third complete remission. The primary
endpoint of the trial is progression-free survival. Secondary
outcome measures include overall survival, measurement of
Hedgehog ligand expression in archival tissue, and number
and attribution of adverse events.
12.MTOR Inhibitors
Numerous investigators have reported alterations in PTEN
in gynecological malignancies [101]. PTEN is a lipid phos-
phatase that is associated with cell cycle G1-phase arrest
andapoptosis through the PI3K/AKT/mTOR pathway[102].
The mTOR pathway is a central regulator of cell growth,
proliferation, and apoptosis. The loss of functional PTEN
either through deletion, mutation, or inactivation leads to
the constitutive activation of PI3K eﬀectors in the absence of
exogenous stimuli. Potential therapies targeting the mTOR
pathway include mTOR inhibitors Temsirolimus (CCI-779),
everolimus (RAD001), and deforolimus (AP23573).
In ovarian cancer, AKT activity is frequently elevated
and is closely associated with the upregulation of mTOR
signaling [103]. High levels of AKT activity in vitro result in
hypersensitivity to mTOR inhibitors [103]. An in vivo study
[104]usingxenograftsofSKOV-3cellsrevealedthatRAD001
inhibited tumor growth, angiogenesis, and production of
ascites suggesting the potential of mTOR inhibitors in the
treatment of women with ovarian cancer.
GOG trial 170I has recently closed a Phase II Evaluation
of Temsirolimus (CCI-779, mTOR inhibitor) in the Treat-
ment of Persistent or Recurrent Epithelial Ovarian, Fallopian
Tube or Primary Peritoneal Carcinoma. Currently recruiting
studies include (NCT00926107), a study of the mTOR
inhibitor Temsirolimus (CCI-779) to treat ovarian cancer
with Ca125 relapse only, a Phase I study of DOXIL and Tem-
sirolimusinResistantSolidMalignanciesNCT00703170,and
a Phase I study of Docetaxel and Temsirolimus in resistant
solid malignancies (NCT00703625).
13. Conclusion
Multiple attractive targets for the design of targeted ther-
apeutics in ovarian cancer are currently under investi-
gation. Recent studies employing monoclonal antibodies
have revealed improvements in time to progression. Studies
with tyrosine kinases inhibitors remain in their infancy of
development but have provided the basis for continued
research.
Despite these advances there are multiple goals for
the future. These include a better understanding of the
redundant pathways that exist in cell signaling, creative
targeting of horizontal and vertical signaling pathways,
identiﬁcation of other predictive markers to better identify
a targeted subpopulation of patients that will respond, and
an underlying of the mechanisms of resistance. Achieving
these goals will be of paramount importance in the study of
targeted therapy in ovarian cancer.
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